Dr. Mike Tranfaglia shares what FRAXA is excited about as we work through reviewing all of the submitted Fragile X research grant applications. We find it especially exciting that so many new clinical trials are starting right now, as our major emphasis is getting the drugs and other treatment strategies that we have tested in the Fragile X mouse model to patients in clinical trials.
FRAXA continues to employ a multipronged strategy to develop new treatments for Fragile X. Our drug repurposing efforts are ongoing, and we are collaborating with several drug repurposing companies. We believe this will result in at least two more Fragile X clinical trials over the next year.
FRAXA funds cutting-edge research in university labs around the world. We have recently begun funding a new lab that will employ recently developed mRNA vaccine technology to produce the missing Fragile X protein.